Previous post Next post

Novartis acquires British start-up Myricx Bio

Swiss pharmaceutical giant Novartis has agreed to pay an initial sum of $1.1 billion (CHF883 million) to acquire the British start-up Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours. The agreement also provides for a further payment of up to CHF400 million, subject to the achievement of predefined milestones, the two companies said in separate statements on Monday. Founded in 2019 as a spin-off from Imperial College London and the Francis Crick Institute, Myricx Bio is developing two antibody-drug conjugates, still at the preclinical stage, to treat various types of solid tumours. These experimental inhibitors target the enzyme N-myristoyltransferase (NMT), which is essential for the survival and proliferation of cancer cells. The company had raised £90 million in 2024 from investors including Novo Holdings, Abingworth, the British Business Bank, Cancer Research Horizons and Eli Lilly. This acquisition is part of Novartis’ stated aim ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,

Permanent link to this article: https://snbchf.com/2026/07/novartis-acquires-british-start-myricx-bio/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.